Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage biotechnology company specializing in gene editing. The company focuses on developing treatments for genetic diseases using CRISPR/Cas9 technology. Intellia's competitors include other biotech firms like CRISPR Therapeutics and Editas Medicine. Recently, JMP Securities set a price target of $29 for NASDAQ:NTLA, while the stock was trading at $14.79, indicating a potential 96% increase.
However, Intellia faces challenges with its MAGNITUDE clinical trials for the Nex-Z treatment. A safety event led to a protocol pause, impacting the development timeline. This pause follows a serious liver issue in a patient, prompting a temporary halt in dosing and screening. The trials focus on a one-time gene-editing therapy for heart conditions.
The announcement of the trial pause was discussed in a conference call with Intellia's leadership, including CEO John Leonard and CMO David Lebwohl. The call involved major financial institutions like Jefferies LLC and Goldman Sachs Group, Inc. This pause is a precautionary measure to ensure patient safety and involves consulting with experts and regulatory authorities.
Currently, NTLA's stock is priced at $13.97, reflecting a 5.54% decrease. The stock has fluctuated between $13.73 and $14.79 during the day. Over the past year, it reached a high of $28.25 and a low of $5.90. NTLA has a market capitalization of approximately $1.5 billion, with a trading volume of 6,346,233 shares on the NASDAQ exchange.
